{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:21Z","timestamp":1787894301317,"version":"build-2784847793"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Elexacaftor\/tezacaftor\/ivacaftor (ETI) is the standard of care for most people with cystic fibrosis (CF) who carry at least one F508del allele. However, predicting responses to CFTR modulators in rare or complex\n                      <jats:italic>CFTR<\/jats:italic>\n                      genotypes is challenging. Sweat chloride concentration (SCC) and patient-derived functional assays assessing CFTR-mediated chloride transport are commonly used to classify modulator responsiveness. Carriers of the p.Leu467Phe;p.Phe508del (henceforward legacy nomenclature: L467F;F508del) complex\n                      <jats:italic>CFTR<\/jats:italic>\n                      allele have been considered unlikely to respond to ETI, based on short-term clinical, biomarker and\n                      <jats:italic>ex vivo<\/jats:italic>\n                      evidence. We report a discordant long-term response in an adult carrying this complex allele, with clinically meaningful benefit despite persistently negative CFTR chloride transport biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We describe an 8-year longitudinal pre- and post-treatment assessment of an adult woman with CF, adherent to therapy, with the L467F;F508del complex allele compounded with the non-responsive c.489\u2009+\u20091G\u2009&amp;gt;\u2009T (621\u2009+\u20091G\u2009&amp;gt;\u2009T) variant in\n                      <jats:italic>trans<\/jats:italic>\n                      . She has pancreatic insufficiency, progressive lung disease, and recurrent pulmonary exacerbations. After ETI commencement (at 40.5 years; July 2021) SCC remained unchanged at \u223c100\u2005mmol\/L. Intestinal organoid and primary nasal epithelial cell assays showed no measurable ETI-related CFTR-mediated chloride transport rescue. Nevertheless, BMI increased from 22.0 to 26.8\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , annual exacerbations decreased from 5 to 3, and ppFEV\u2081 improved from 51% to 55\u201359%. Serial chest CT showed a shift from pre-ETI progression to post-ETI stabilisation, with reductions in air trapping and the extent of bronchiectasis on manual Brody II scoring and LungQ\/PRAGMA-AI quantification. Exploratory\n                      <jats:italic>in vitro<\/jats:italic>\n                      exposure of nasal epithelial cells to vanzacaftor\/tezacaftor\/ivacaftor yielded \u223c5% CFTR-mediated rescue, contrasting with the negative ETI response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Persistent CFTR biomarker negativity may not fully exclude clinically meaningful ETI-associated benefit in rare or complex\n                      <jats:italic>CFTR<\/jats:italic>\n                      genotypes. The pulmonary and extrapulmonary improvements observed in this case support multidimensional response assessment beyond single-biomarker endpoints. These hypothesis-generating observations support individualised long-term monitoring and comprehensive interpretation of CFTR biomarkers in the clinical context. AI-assisted chest CT may provide complementary real-world evidence. An exploratory\n                      <jats:italic>in vitro<\/jats:italic>\n                      rescue study with vanzacaftor\/tezacaftor supports the evaluation of emerging CFTR modulators. It suggests that similar studies should be conducted in other cases involving complex\n                      <jats:italic>CFTR<\/jats:italic>\n                      alleles.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1930172","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:32:01Z","timestamp":1787891521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical benefit without sweat chloride response after ETI therapy in an adult with cystic fibrosis bearing the L467F;F508del complex CFTR allele: a case report and the role of AI-assisted chest CT in longitudinal monitoring"],"prefix":"10.3389","volume":"13","author":[{"given":"Marcela","family":"Kreslova","sequence":"first","affiliation":[{"name":"Department of Paediatrics, University Hospital, Faculty of Medicine in Pilsen, Charles University","place":["Pilsen, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Caudri","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Division of Respiratory Medicine and Allergy, Erasmus MC\u2013Sophia Children\u2019s Hospital, University Medical Centre Rotterdam","place":["Rotterdam, Netherlands"]},{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC\u2013Sophia Children\u2019s Hospital, University Medical Centre Rotterdam","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[{"name":"Institut Necker Enfants Malades, INSERM, Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Hatton","sequence":"additional","affiliation":[{"name":"Institut Necker Enfants Malades, INSERM, Universit\u00e9 Paris Cit\u00e9","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punitkumar","family":"Makani","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Division of Respiratory Medicine and Allergy, Erasmus MC\u2013Sophia Children\u2019s Hospital, University Medical Centre Rotterdam","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Koucky","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Libik","sequence":"additional","affiliation":[{"name":"Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Hrdinova","sequence":"additional","affiliation":[{"name":"Department of Imaging Methods, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Fila","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nela","family":"Stastna","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Furstova","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, First Faculty of Medicine, Charles University, Thomayer University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Bittenglova","sequence":"additional","affiliation":[{"name":"Department of Pneumology, University Hospital, Faculty of Medicine in Pilsen, Charles University","place":["Pilsen, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Baxa","sequence":"additional","affiliation":[{"name":"Department of Imaging Methods, NH Hospital, AKESA Holding","place":["Horovice, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Sykora","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University Hospital, Faculty of Medicine in Pilsen, Charles University","place":["Pilsen, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Macek","sequence":"additional","affiliation":[{"name":"Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University, Motol and Homolka University Hospital","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B2","year":"2026"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients: the value of the ex vivo nasal epithelial model to address non-responders to CFTR-modulating drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"00108-6","DOI":"10.1016\/j.jcf.2026.05.002","article-title":"Cftr modulator therapy reshapes airway inflammation in cystic fibrosis: insights from proteomics and machine learning","author":"\u00c5rman","year":"2026","journal-title":"J Cyst Fibros"},{"key":"B8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jcf.2026.04.013","article-title":"Ecfs statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF","volume":"25","author":"De Boeck","year":"2026","journal-title":"J Cyst Fibros"},{"key":"B9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jpeds.2004.02.038","article-title":"High\u2013resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests","volume":"145","author":"Brody","year":"2004","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/thorax-2023-220021","article-title":"Automatic analysis of bronchus-artery dimensions to diagnose and monitor airways disease in cystic fibrosis","volume":"79","author":"Lv","year":"2024","journal-title":"Thorax"},{"key":"B11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jcf.2025.08.003","article-title":"Validation of an artificial intelligence-based automated PRAGMA and mucus plugging algorithm in pediatric cystic fibrosis","volume":"24","author":"Raut","year":"2025","journal-title":"J Cyst Fibros"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2400156","DOI":"10.1183\/13993003.00156-2024","article-title":"Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay","volume":"63","author":"Furstova","year":"2024","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"10377","DOI":"10.3390\/ijms231810377","article-title":"Evaluation of the complex p.[Leu467Phe;Phe508del] CFTR allele in the intestinal organoids model: implications for therapy","volume":"23","author":"Kondratyeva","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1159\/000543009","article-title":"The proof of the pudding is in the eating: real-life intra- and extrapulmonary impact of elexacaftor\/tezacaftor\/ivacaftor","volume":"104","author":"Vincken","year":"2025","journal-title":"Respiration"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1178009","DOI":"10.3389\/fphar.2023.1178009","article-title":"Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study","volume":"14","author":"Fila","year":"2023","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2500778","DOI":"10.1183\/13993003.00778-2025","article-title":"Theratyping in cystic fibrosis: filling the knowledge gaps","volume":"65","author":"Pranke","year":"2025","journal-title":"Eur Respir J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1245885","DOI":"10.3389\/fphar.2023.1245885","article-title":"Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study","volume":"14","author":"Dettmer","year":"2023","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jcf.2025.12.018","article-title":"Rethinking CFTR variant responsiveness: differential responses to vanzacaftor and elexacaftor","volume":"25","author":"Rodriguez Mier","year":"2026","journal-title":"J Cyst Fibros"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2026.05.015","article-title":"Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-resistant L467F-F508del Allele: ex vivo prediction and exploratory clinical assessment","author":"Capurro","year":"2026","journal-title":"J Cyst Fibros"},{"key":"B20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jcf.2023.02.012","article-title":"When triple therapy is not working: a reverse iceberg perspective","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1930172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:32:09Z","timestamp":1787891529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1930172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1930172"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1930172","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1930172"}}